产品
编 号：F356272
产品类型
规格
价格
是否有货
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
结构图
CAS No: 428863-50-7
产品详情
生物活性：
Certolizumab pegol (Certolizumab) is a recombinant, polyethylene glycolylated, antigen-binding fragment of a humanized monoclonal antibody that selectively targets and neutralizes tumour necrosis factor-α (TNF-α). Certolizumab pegol can be used for rheumatoid arthritis and Crohn disease research.
体内研究：
Certolizumab pegol (Certolizumab) (10 μg；腹腔注射；单剂量) 可降低急性胰腺炎的严重程度。Animal Model:Healthy Wistar Albino male rats weighing 180 to 200 g, acute edematous pancreatitis was induced via intraperitoneal injection of 80 μg/kg Cerulein (HY-A0190) (20 μg/kg, 4 times at 1-hour intervals)
Dosage:10 μg
Administration:Intraperitoneal administration, single dose
Result:Significantly decreased the serum levels of amylase, lipase, and lactate dehydrogenase. Histopathological edema, hemorrhage, parenchymal necrosis, and infiltration scores were also decreased, along with a decrease in malondialdehyde, myeloperoxidase, TNF-α, and caspase-3 activities.
体外研究：
Certolizumab pegol (Certolizumab) 中和可溶性 TNFα，IC90 为 3 ng/mL。 Certolizumab pegol (0-100 μg/mL，1 h) 完全抑制人单核细胞响应 LPS 产生的 IL-1β。 Certolizumab pegol 不介导补体依赖性细胞毒性 (CDC) 或抗体依赖性细胞介导的细胞毒性 (ADCC)。 Certolizumab pegol 不会诱导活化的人单核细胞或外周血淋巴细胞 (PBL) 的凋亡，也不会导致脱颗粒或丢失多形核细胞的细胞膜完整性。
Certolizumab pegol (Certolizumab) is a recombinant, polyethylene glycolylated, antigen-binding fragment of a humanized monoclonal antibody that selectively targets and neutralizes tumour necrosis factor-α (TNF-α). Certolizumab pegol can be used for rheumatoid arthritis and Crohn disease research.
体内研究：
Certolizumab pegol (Certolizumab) (10 μg；腹腔注射；单剂量) 可降低急性胰腺炎的严重程度。Animal Model:Healthy Wistar Albino male rats weighing 180 to 200 g, acute edematous pancreatitis was induced via intraperitoneal injection of 80 μg/kg Cerulein (HY-A0190) (20 μg/kg, 4 times at 1-hour intervals)
Dosage:10 μg
Administration:Intraperitoneal administration, single dose
Result:Significantly decreased the serum levels of amylase, lipase, and lactate dehydrogenase. Histopathological edema, hemorrhage, parenchymal necrosis, and infiltration scores were also decreased, along with a decrease in malondialdehyde, myeloperoxidase, TNF-α, and caspase-3 activities.
体外研究：
Certolizumab pegol (Certolizumab) 中和可溶性 TNFα，IC90 为 3 ng/mL。 Certolizumab pegol (0-100 μg/mL，1 h) 完全抑制人单核细胞响应 LPS 产生的 IL-1β。 Certolizumab pegol 不介导补体依赖性细胞毒性 (CDC) 或抗体依赖性细胞介导的细胞毒性 (ADCC)。 Certolizumab pegol 不会诱导活化的人单核细胞或外周血淋巴细胞 (PBL) 的凋亡，也不会导致脱颗粒或丢失多形核细胞的细胞膜完整性。
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备